BioSpace News Archive

Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma

In September, the trial’s Data Monitoring Committee (DMC) determined that the fourth cohort single dose of 31.25 mCi/m2 was safe and tolerated.

October 24, 2017

·

6 min read

Drug Development

Sienna Biopharmaceuticals Announces First Patient Dosed in Phase IIb Trial of Topical SNA-120

The trial has 190 patients with at least moderate pruritus and mild-to-moderate psoriasis.

October 24, 2017

·

5 min read

BioCapital

K2M to Feature First FDA-Cleared 3D-Printed Expandable Interbody System, Industry-Leading 3D-Printed Portfolio, & Balance ACS Platform at NASS 2017

Favorable data on K2M’s cervical spinal solutions to be presented during scientific sessions.

October 24, 2017

·

11 min read

Policy

Myriad Submits BRACAnalysis CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer

Myriad estimates there are greater than 10,000 cases of HER2- metastatic breast cancer per year in Japan which would be eligible for testing with BRACAnalysis CDx.

October 24, 2017

·

6 min read

Drug Development

Rhizen Pharmaceuticals S.A. Announces Preclinical Data Presentations for RP4010, a Novel First-in-Class Oral Small Molecule Inhibitor of Calcium Release-Activated Calcium (CRAC) Channel at 2017 AACR-NCI-EORTC International Conference, USA

October 24, 2017

·

2 min read

Business

Resverlogix Announces Right of First Refusal Agreement With Hepalink USA

Hepalink paid $8 million (the “Fee”) to Resverlogix in consideration for the right of first refusal granted.

October 24, 2017

·

4 min read

Drug Development

U.S. FDA Grants Orphan Drug Designation To Zealand Pharma’s Glepaglutide for the Treatment of Short Bowel Syndrome

Glepaglutide is a Zealand-invented long-acting GLP-2 analog that may offer a treatment option for patients with reduced or complete loss of intestinal function.

October 24, 2017

·

2 min read

Policy

ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431

ContraVir will utilize preclinical services from the NIAID to characterize the antiviral activity of CRV431 in a humanized mouse model of hepatitis B virus infection.

October 24, 2017

·

4 min read

Pharm Country

USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor

This issued patent will be the eighth patent that the USPTO has granted to Achillion this year on its complement factor D portfolio.

October 24, 2017

·

5 min read

Business

BioCryst to Announce Third Quarter 2017 Financial Results on November 7

BioCryst will host a conference call and webcast at 11:00 a.m. ET to discuss financial results and to provide an update regarding the Company’s clinical development programs.

October 24, 2017

·

1 min read